鄭敏
查看科室更多醫(yī)生性 別：女
最高學(xué)歷,、學(xué)位：博士研究生,、博士
職 稱：教授
院內(nèi)職務(wù)：副院長(zhǎng),，傳染病診治國(guó)家重點(diǎn)實(shí)驗(yàn)室副主任
個(gè)人簡(jiǎn)介
浙江大學(xué)求是特聘科研崗,，教授,，博士生導(dǎo)師,，浙江省“萬(wàn)人計(jì)劃”科技創(chuàng)新領(lǐng)軍人才,，浙江省高校高水平創(chuàng)新“肝病精準(zhǔn)診治”團(tuán)隊(duì)帶頭人,，省151 人才。長(zhǎng)期致力于慢乙肝重癥化發(fā)病機(jī)制與精準(zhǔn)診治研究,。主持“十三五”科技部重大專項(xiàng)1項(xiàng),，“十二五”科技部重大專項(xiàng)子任務(wù)1項(xiàng)，國(guó)自然聯(lián)合基金重點(diǎn)支持項(xiàng)目1項(xiàng),，國(guó)家自然基金面上項(xiàng)目 4 項(xiàng),，浙江省重點(diǎn)研發(fā)計(jì)劃2項(xiàng)。在高水平專業(yè)學(xué)術(shù)期刊上發(fā)表論文 80 余篇,，近五年以通訊作者（含共同通訊）在《BMJ》,、《Adv Sci》、《Genome Biol》,、《Biotechnol Adve》和《J Hematol Oncol》等期刊發(fā)表論文30余篇,。授權(quán)發(fā)明專利 10 余項(xiàng)，參編著作2部,，多次獲得教育部及浙江省科技進(jìn)步獎(jiǎng),。
專業(yè)擅長(zhǎng)
主要從事傳染病學(xué)的教學(xué)與科研工作,。擅長(zhǎng)重癥肝病精準(zhǔn)診治和重大傳染性疾病防治的基礎(chǔ)與臨床研究。
研究方向
致力于從多角度解析乙肝重癥化轉(zhuǎn)歸的機(jī)制,，探索創(chuàng)建重癥肝病精準(zhǔn)診療的新技術(shù),。研究方向?yàn)镠BV感染、慢乙肝轉(zhuǎn)歸,、肝臟炎癌轉(zhuǎn)化過(guò)程中的分子和免疫機(jī)制,，肝病精準(zhǔn)診斷和藥物靶點(diǎn)及靶向治療藥物的研發(fā)工作。
成果獎(jiǎng)項(xiàng)：（近五年主要成果及獎(jiǎng)勵(lì)情況）
近5年以通訊或共同通訊發(fā)表SCI論文31篇：
Shi D, Weng T, Wu J, Dai C, Luo R, Chen K, Zhu M, Lu X, Cheng L, Chen Q, Liu F, Wu Z, Wu H, Jin C, Guo M, Chen Z, Wu N, Yao H*, Zheng M*. Dynamic Characteristic Analysis of Antibodies in Patients With COVID-19: A 13-Month Study. Front Immunol. 2021 Jul 20;12:708184.
Chen B, Wang W, Xu W, Ying L, Zhou C*, Zheng M*. Serum free light chain is associated with histological activity and cirrhosis in patients with chronic hepatitis B. Int Immunopharmacol. 2021 Jul 7;99:107881.
Ruan D, Shi Y, Wen J, Zheng N*, Zheng M*. Spatially-Aware Context Neural Networks. IEEE Trans Image Process. 2021 Jul 26;PP.
Ruan D, Shi Y, Jin L, Yang Q, Yu W, Ren H, Zheng W, Chen Y, Zheng N*, Zheng M*. An Ultrasound Image-Based Deep Multi-Scale Texture Network for Liver Fibrosis Grading in Patients with Chronic HBV Infection. Liver Int. 2021 Jul 5.
Chen Y, Yao H, Zhang N, Wu J, Gao S, Guo J, Lu X, Cheng L, Luo R, Liang X, Wong CCL*, Zheng M*. Proteomic Analysis Identifies Prolonged Disturbances in Pathways Related to Cholesterol Metabolism and Myocardium Function in the COVID-19 Recovery Stage. J Proteome Res. 2021 Jun 3.
Guo H, Chen S, Xie M, Zhou C*, Zheng M*. The complex roles of neutrophils in APAP-induced liver injury. Cell Prolif. 2021 Jun;54(6):e13040.
Chen S, Guo H, Xie M, Zhou C*, Zheng M*. Neutrophil: An emerging player in the occurrence and progression of metabolic associated fatty liver disease. Int Immunopharmacol. 2021 Apr 19;97:107609.
Li S, Shao J, Lou G, Wu C, Liu Y*, Zheng M*. MiR-144-3p-mediated dysregulation of EIF4G2 contributes to the development of hepatocellular carcinoma through the ERK pathway. J Exp Clin Cancer Res. 2021 Feb 1;40(1):53.
Wang W, Shui L, Liu Y*, Zheng M*. C-Kit, a Double-Edged Sword in Liver Regeneration and Diseases. Front Genet. 2021 Feb 2;12:598855.
Xie M, Guo H, Lou G, Yao J, Liu Y, Sun Y*, Yang Z*, Zheng M*. Neddylation inhibitor MLN4924 has anti-HBV activity via modulating the ERK-HNF1α-C/EBPα-HNF4α axis. J Cell Mol Med. 2021 Jan;25(2):840-854.
Yetian Dong, Tong Dai, Yujun Wei, Long Zhang, Min Zheng*, Fangfang Zhou*. A systematic review of SARS-CoV-2 vaccine candidates. Signal Transduct Target Ther. 2020 Oct 13;5(1):237.
Xia C, Zhu W, Huang C, Lou G, Ye B, Chen F, Chen Z, Liu Y, Zheng M. Genetic polymorphisms of interleukin-6 influence the development of hepatitis B virus-related liver cirrhosis in the Han Chinese population. Infect Genet Evol. 2020 Apr 27;84:104331.
Shi Y, Zheng M*. Hepatitis B virus persistence and reactivation. BMJ. 2020 Sep 1;370:m2200.
Shi Y, Wang G, Cai XP, Deng JW, Zheng L, Zhu HH, Zheng M, Yang B, Chen Z. An Overview of COVID-19. J Zhejiang Univ Sci B. 2020 May;21(5):343-360.
Zhang X, Peng Z, Li C, Wang Z, Wang C, Deng Z, Wu B, Cui Y, Wang Z, Cui CP*, Zheng M*, Zhang L*.Deubiquitylase OTUD6B Governs pVHL Stability in an Enzyme-Independent Manner and Suppresses Hepatocellular Carcinoma Metastasis. Adv Sci (Weinh). 2020 Jan.
Shao J, Li S, Liu Y*, Zheng M*.Extracellular vesicles participate in macrophage-involved immune responses under liver diseases. Life Sci. 2020 Jan.
Lou G, Chen L, Xia C, Wang W, Qi J, Li A, Zhao L, Chen Z, Zheng M*, Liu Y*.MiR-199a-modified exosomes from adipose tissue-derived mesenchymal stem cells improve hepatocellular carcinoma chemosensitivity through mTOR pathway. J ExpClin Cancer Res. 2020 Jan.
Zhou X, Liu Z, Wang H, Liu X, Zhou Z, Tang J, Liu X*, Zheng M*, Shen Y. SAHA (vorinostat) facilitates functional polymer-based gene transfection via upregulation of ROS and synergizes with TRAIL gene delivery for cancer therapy. JOURNAL OF DRUG TARGETING. 2019 Jan.
Guo H, Xie M, Zhou C*, Zheng M*.The relevance of pyroptosis in the pathogenesis of liver diseases. Life Sci. 2019,223:69-73.
Ye B, Zhou C, Guo H, Zheng M*.Effects of BTK signalling in pathogenic microorganism infections. J Cell Mol Med. 2019 Jun.
Li Z, Leustean L, Inci F, Zheng M*, Demirci U*, Wang S*. Plasmonic-based platforms for diagnosis of infectious diseases at the point-of-care. Biotechnology Advances. 2019 Jul.
Xiao Z, Cheng G, Jiao Y, Pan C, Li R, Jia D, Zhu J, Wu C*, Zheng M*, Jia J*. Holo-Seq: single-cell sequencing of holo-transcriptome. Genome Biol. 2018 Feb.
Li S, Yao J, Xie M, Liu Y, Zheng M*. Exosomal miRNAs in hepatocellular carcinoma development and clinical responses. J HematolOncol. 2018 Mar.
Liu Y*, Lou G, Li A, Zhang T, Qi J, Ye D, Zheng M*, Chen Z. AMSC-derived exosomes alleviate lipopolysaccharide/d-galactosamine-induced acute liver failure by miR-17-mediated reduction of TXNIP/NLRP3 inflammasome activation in macrophages. EBioMedicine. 2018 Aug.
Jiao Y, Li R, Wu C, Ding Y, Liu Y, Jia D, Wang L, Xu X, Zhu J, Zheng M*, Jia J*.High-sensitivity HLA typing by Saturated Tiling Capture Sequencing (STC-Seq). BMC Genomics. 2018 Sep.
Zheng W, Ye B, Liang X, Shui L, Lou G, Liu Y, Zheng M*. Hepatic macrophages are the cell source of hepatic procalcitonin in acute liver failure. Cell PhysiolBiochem. 2018 Sep.
Xie M, Yang Z, Liu Y, Zheng M*.The role of HBV-induced autophagy in HBV replication and HBV related-HCC. Life Sci. 2018 Apr.
Wu C, Jiao Y, Shen M, Pan C, Cheng G, Jia D, Zhu J, Zhang L, Zheng M*, Jia J*.Clustering-local-unique-enriched-signals (CLUES) promotes identification of novel regulators of ES cell self-renewal and pluripotency. PLoS One. 2018 Oct.
Zheng W, Liang X, Shui L, Ye B, Lou G, Liu Y, Zheng M*.Serum Procalcitonin Correlates with Renal Function in Hepatitis B Virus-Related Acute-on-Chronic Liver Failure. Cell PhysiolBiochem. 2018 Oct.
Lou G, Yang Y, Liu F, Ye B, Chen Z, Zheng M*, Liu Y*.MiR-122 Modification Enhances the Therapeutic Efficacy of Adipose Tissue-derived MSCs against Liver Fibrosis. J Cell Mol Med. 2017 Jan.
Xia C, Shui L, Lou G, Ye B, Zhu W, Wang J, Wu S, Xu X, Mao L, Xu W, Chen Z, Liu Y, Zheng M*. 0404 inhibits hepatocellular carcinoma through a p53/miR-34a/SIRT1 positive feedback loop. Sci Rep. 2017 Apr.
近5年作為第一發(fā)明人授權(quán)專利5項(xiàng)：
1) 與乙型肝炎肝硬化相關(guān)的IL-6基因rs2069837位點(diǎn)標(biāo)志物及其應(yīng)用, ZL201610115774.8, 授權(quán)公告日2020年7月21日,。
2) 與乙型肝炎肝硬化相關(guān)的IL-6基因rs10499563位點(diǎn)標(biāo)志物及其應(yīng)用, ZL201610116342.9, 授權(quán)公告日2020年8月7日,。
3) 與慢性乙型肝炎病毒感染相關(guān)的IL-6基因SNP標(biāo)志物及其應(yīng)用,ZL201610115674.5, 授權(quán)公告日2020年8月7日。
4) 與慢性乙型肝炎病毒感染相關(guān)的IL-6基因SNP標(biāo)志物及其應(yīng)用, ZL201610116319X, 授權(quán)公告日2020年5月5日,。
5) 與慢性乙型肝炎病毒感染相關(guān)的IL-6基因rs2069852位點(diǎn)標(biāo)志物及其應(yīng)用,。中國(guó)(ZL201610116382.3)。授權(quán)公告日2019年2月26日,。
獲獎(jiǎng)情況：
1. 2019年,，長(zhǎng)三角生物工程優(yōu)秀青年學(xué)者獎(jiǎng)
2. 2018年，浙江省高校高水平創(chuàng)新團(tuán)隊(duì),，團(tuán)隊(duì)帶頭人
3. 2018年,，病毒性肝炎發(fā)病機(jī)制及轉(zhuǎn)歸預(yù)警預(yù)測(cè)的基礎(chǔ)研究，浙江省自然科學(xué)獎(jiǎng)二等獎(jiǎng),，排名2/5
4. 2018年,，整合醫(yī)學(xué)背景下的研究生“會(huì)聚式”協(xié)同培養(yǎng)模式的探索與實(shí)踐，浙江省研究生教育學(xué)會(huì)教育成果獎(jiǎng)特等獎(jiǎng),，排名5/12
社會(huì)任職
中華預(yù)防醫(yī)學(xué)會(huì)微生態(tài)學(xué)分會(huì)第五屆委員會(huì) 委員
中華醫(yī)學(xué)會(huì)肝病學(xué)分會(huì)第七屆委員會(huì)青年委員會(huì) 委員
中華醫(yī)學(xué)會(huì)醫(yī)學(xué)科學(xué)研究管理學(xué)分會(huì)青年委員會(huì) 委員
浙江省醫(yī)學(xué)會(huì)肝病學(xué)分會(huì)第四屆委員會(huì) 副主任委員
浙江省醫(yī)學(xué)會(huì)科學(xué)研究管理分會(huì)委員會(huì) 副主任委員
